Is OPKO HEALTH, INC. (OPK) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 55.7% / 30% | 47.7% / 30% | 16.8% / 30% | 1.18% / 5% | ✗ NOT HALAL |
| DJIM | 55.7% / 33% | 47.7% / 33% | 16.8% / 33% | 1.18% / 5% | ✗ NOT HALAL |
| MSCI | 22.9% / 33% | 19.6% / 33% | 6.9% / 33% | 1.18% / 5% | ✓ HALAL |
| S&P | 55.7% / 33% | 47.7% / 33% | 16.8% / 33% | 1.18% / 5% | ✗ NOT HALAL |
| FTSE | 22.9% / 33% | 19.6% / 33% | 6.9% / 50% | 1.18% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 13.5% | |
| Operating Margin | -29.0% | |
| Net Margin | -37.2% | |
| Return on Equity (ROE) | -17.1% | |
| Return on Assets (ROA) | -6.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$179M |
| Free Cash Flow | -$191M |
| Total Debt | $397M |
| Debt-to-Equity | 31.3 |
| Current Ratio | 4.0 |
| Total Assets | $1.9B |
Price & Trading
| Last Close | $1.17 |
| 50-Day MA | $1.22 |
| 200-Day MA | $1.33 |
| Avg Volume | 3.0M |
| Beta | 1.5 |
|
52-Week Range
$1.10
| |
About OPKO HEALTH, INC. (OPK)
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is OPKO HEALTH, INC. (OPK) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), OPKO HEALTH, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is OPKO HEALTH, INC.'s debt ratio?
OPKO HEALTH, INC.'s debt ratio is 55.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 22.9%.
What are OPKO HEALTH, INC.'s key financial metrics?
OPKO HEALTH, INC. has a market capitalization of $860M, and revenue of $607M. The company maintains a gross margin of 13.5% and a net margin of -37.2%. Return on equity stands at -17.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.